CD28 and neoplasm: A clinical study in non-Hodgkin’s lymphoma showed that CD28-based CAR-T and 4-1BB-based CAR-T cells exhibited similar anti-tumor effects at 3 months post-treatment, but CD28-based CAR-T cells induced more severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) (NCT03528421) (36).